Chromosome 5 and 7 Abnormalities in Oncology Personnel Handling Anticancer Drugs

被引:91
作者
McDiarmid, Melissa A. [1 ]
Oliver, Marc S. [1 ]
Roth, Tracy S. [1 ]
Rogers, Bonnie [2 ]
Escalante, Carmen [3 ]
机构
[1] Univ Maryland, Sch Med, Dept Med, Occupat Hlth Program, Baltimore, MD 21201 USA
[2] Univ N Carolina, Sch Publ Hlth, Occupat Hlth Nursing Program, Chapel Hill, NC USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gen Med, Houston, TX 77030 USA
关键词
IN-SITU HYBRIDIZATION; MONITORING OCCUPATIONAL-EXPOSURE; ACUTE MYELOID-LEUKEMIA; HEALTH-CARE WORKERS; ANTINEOPLASTIC AGENTS; PHARMACY TECHNICIANS; BONE-MARROW; LYMPHOCYTES; POPULATION; INTERPHASE;
D O I
10.1097/JOM.0b013e3181f73ae6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To determine the frequency of "signature" chromosomal abnormalities in oncology workers handling anticancer drugs. Methods: Peripheral blood from health care personnel (N = 109) was examined with probes for targets on chromosomes 5, 7, and 11. The effect of drug-handling frequency on chromosome abnormalities was assessed. Results: An excess of structural (0.18 vs 0.02; P = 0.04) and total abnormalities (0.29 vs 0.04; P = 0.01) of chromosome 5 was observed in the high-exposure group compared with the unexposed. Increased incidence rate ratios (IRRs) for abnormalities of chromosome 5 (IRR = 1.24; P = 0.01) and for either chromosome 5 or 7 (IRR = 1.20; P = 0.01) were obtained at 100 handling events. Effect sizes were augmented 2- to 4-fold when alkylating agent handling alone was considered. Conclusions: Biologically important exposure to genotoxic drugs is apparently occurring in oncology work settings despite reported use of safety practices.
引用
收藏
页码:1028 / 1034
页数:7
相关论文
共 50 条
[1]   RISK OF HANDLING INJECTABLE ANTI-NEOPLASTIC AGENTS [J].
ANDERSON, RW ;
PUCKETT, WH ;
DANA, WJ ;
NGUYEN, TV ;
THEISS, JC ;
MATNEY, TS .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1982, 39 (11) :1881-1887
[2]  
[Anonymous], 1987, ENVIRON HEALTH PERSP, V74, P3
[3]  
[Anonymous], 1990, AM J HOSP PHARM, V47, P1033
[4]  
[Anonymous], 2006, AM J HEALTH-SYST PH, V63, P1172
[5]  
[Anonymous], 2009, BIOL AG IARC MON EV
[6]  
[Anonymous], 2000, WILEY PS TX, DOI 10.1002/0471722146
[7]   Monitoring occupational exposure to cancer chemotherapy drugs [J].
Baker, ES ;
Connor, TH .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (22) :2713-2723
[8]  
Burroughs G., 2014, PUBL2004165 DHHS NIO
[9]   Preventing occupational exposures to antineoplastic drugs in health care settings [J].
Connor, Thomas H. ;
McDiarmid, Melissa A. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (06) :354-365
[10]   Evaluation of Antineoplastic Drug Exposure of Health Care Workers at Three University-Based US Cancer Centers [J].
Connor, Thomas H. ;
DeBord, Gayle ;
Pretty, Jack R. ;
Oliver, Marc S. ;
Roth, Tracy S. ;
Lees, Peter S. J. ;
Krieg, Edward F., Jr. ;
Rogers, Bonnie ;
Escalante, Carmen P. ;
Toennis, Christine A. ;
Clark, John C. ;
Johnson, Belinda C. ;
McDiarmid, Melissa A. .
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2010, 52 (10) :1019-1027